Pancreatic Cancer:Assay for Early Detection

胰腺癌：早期检测检测

• 批准号: 8453974
• 负责人: GARY M NISHIOKA
• 金额: $ 15万
• 依托单位: H AND N INSTRUMENTS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-10 至 2014-09-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8453974
• 关键词: Antibodies; Ascites; Biological Assay; Biological Markers; Blood; CA-19-9 Antigen; Cancer Detection; Cancer Patient; Clinical; Detection; Diagnosis; Diagnostic; Disease; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Future; Gel; Goals; Immunoassay; Laboratories; Laboratory Research; Liquid substance; Malignant Neoplasms; Malignant neoplasm of pancreas; Marketing; Measurement; Measures; Methods; Modeling; Neuropilin-1; Patients; Performance; Phase; Plasma; Procedures; Process; Proteins; Protocols documentation; Reader; Research; Research Personnel; Risk; Serum; Staging; Symptoms; System; Targeted Research; United States; aqueous; base; cancer diagnosis; cationic antimicrobial protein CAP 37; design; digital; instrument; interest; meetings; outcome forecast; pancreatic juice; prospective; public health relevance; sample collection; screening; tool; tumor; tumor growth; validation studies

DESCRIPTION (provided by applicant): The near-term commercial opportunity targets the research market and is a set of diagnostic chips for the measurement of prospective biomarkers of early stage pancreatic cancer. The commercial availability of these chips would increase the odds for researchers in successfully identifying useful biomarkers. In addition, activated, customizable chips would be available to researchers interested in designing assays for pancreatic cancer biomarkers of their own choosing. A turn-key system, including a chip reader would also be available. The ultimate and most important commercial product targets the clinical diagnostic market. It would be a diagnostic assay system for early-stage pancreatic cancer detection. Such a system could be an important screening tool for at-risk patients.

描述（由申请人提供）：近期商业机会针对研究市场，是一套用于测量早期胰腺癌前瞻性生物标志物的诊断芯片。这些芯片的商业可用性将增加研究人员成功识别有用生物标志物的几率。此外，激活的，可定制的芯片将提供给有兴趣设计自己选择的胰腺癌生物标志物测定的研究人员。还将提供一个包括芯片阅读器的交钥匙系统。最终和最重要的商业产品目标是临床诊断市场。这将是一个诊断分析系统，用于早期胰腺癌的检测。这样的系统可以成为高危患者的重要筛查工具。